Boston Scientific Corporation (BSX)Healthcare | Medical Devices | Marlborough, United States | NYSE
44.65 USD
-0.12
(-0.268%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 6:02 a.m. EDT
The investment case here is a classic 'value trap' waiting for a catalyst. Fundamentally, the business is robust with a 11.6% revenue growth trajectory, a 17.3% profit margin, and a forward P/E of just 12x, which implies significant mean reversion potential given the 57% price slump. However, the market has priced in severe structural issues, likely related to the recent guidance cuts mentioned in the news, creating a heavy overhang. The short-term outlook remains murky; the statistical forecast model leans negative (-6.4%), and the options chain is screaming caution with a massive wall of put open interest that suggests traders are betting against a bounce. Until the company clarifies the factors behind the guidance cut and the market absorbs the new reality, the risk of further downside outweighs the immediate upside. Long-term, the fundamentals are strong enough to support a recovery, but the path is currently blocked by sentiment and uncertainty. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.114293 |
| AutoARIMA | 0.152499 |
| AutoETS | 0.152501 |
| MSTL | 0.171173 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 8.80 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.220 |
| Excess Kurtosis | -1.10 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 42.25 |
| Revenue per Share | 13.907 |
| Market Cap | 66,365,763,584 |
| Trailing P/E | 18.68 |
| Forward P/E | 12.03 |
| Beta | 0.58 |
| Profit Margins | 17.29% |
| Website | https://www.bostonscientific.com |
As of July 11, 2026, 6:02 a.m. EDT: Speculators are heavily positioned for downside protection, evidenced by massive open interest in out-of-the-money puts (e.g., 19.9k at $40 strike) compared to calls. While there is some volume in near-term calls, the overwhelming capital allocation is in put writing and buying, suggesting a consensus expectation of continued volatility or a decline toward the $40-$43 support zone.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.56851566 |
| Address1 | 300 Boston Scientific Way |
| All Time High | 109.5 |
| All Time Low | 2.34375 |
| Ask | 44.4 |
| Ask Size | 400 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 19,801,620 |
| Average Daily Volume3 Month | 20,700,752 |
| Average Volume | 20,700,752 |
| Average Volume10Days | 19,801,620 |
| Beta | 0.577 |
| Bid | 0.0 |
| Bid Size | 500 |
| Board Risk | 8 |
| Book Value | 17.402 |
| City | Marlborough |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 4 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 44.65 |
| Current Ratio | 1.9 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 45.43 |
| Day Low | 44.3601 |
| Debt To Equity | 42.25 |
| Earnings Call Timestamp End | 1,785,355,200 |
| Earnings Call Timestamp Start | 1,785,355,200 |
| Earnings Growth | 1.0 |
| Earnings Quarterly Growth | 0.99 |
| Earnings Timestamp | 1,785,328,200 |
| Earnings Timestamp End | 1,785,328,200 |
| Earnings Timestamp Start | 1,785,328,200 |
| Ebitda | 5,500,000,256 |
| Ebitda Margins | 0.26681 |
| Enterprise To Ebitda | 13.851 |
| Enterprise To Revenue | 3.696 |
| Enterprise Value | 76,181,757,952 |
| Eps Current Year | 3.3596 |
| Eps Forward | 3.71058 |
| Eps Trailing Twelve Months | 2.39 |
| Esg Populated | 0 |
| Exchange | NYQ |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 49.622 |
| Fifty Day Average Change | -4.972 |
| Fifty Day Average Change Percent | -0.100197494 |
| Fifty Two Week Change Percent | -56.851566 |
| Fifty Two Week High | 109.5 |
| Fifty Two Week High Change | -64.85 |
| Fifty Two Week High Change Percent | -0.5922374 |
| Fifty Two Week Low | 42.25 |
| Fifty Two Week Low Change | 2.4000015 |
| Fifty Two Week Low Change Percent | 0.05680477 |
| Fifty Two Week Range | 42.25 - 109.5 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 706,282,200,000 |
| Float Shares | 1,482,327,156 |
| Forward Eps | 3.71058 |
| Forward P E | 12.033159 |
| Free Cashflow | 2,807,124,992 |
| Full Exchange Name | NYSE |
| Full Time Employees | 59,000 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.68943 |
| Gross Profits | 14,211,999,744 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0023100001 |
| Held Percent Institutions | 0.94344 |
| Implied Shares Outstanding | 1,486,355,179 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Ir Website | http://phx.corporate-ir.net/phoenix.zhtml?c=62272&p=irol-irhome |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,068,076,800 |
| Last Split Factor | 2:1 |
| Long Business Summary | Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts. |
| Long Name | Boston Scientific Corporation |
| Market | us_market |
| Market Cap | 66,365,763,584 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_317627 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | 3,564,999,936 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 66,365,758,742 |
| Number Of Analyst Opinions | 29 |
| Open | 45.34 |
| Operating Cashflow | 4,341,000,192 |
| Operating Margins | 0.20603001 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Peg Ratio | 0.55 |
| Phone | 508 683 4000 |
| Pre Market Change | -0.65999985 |
| Pre Market Change Percent | -1.4778322 |
| Pre Market Price | 44.0 |
| Pre Market Time | 1,784,031,667 |
| Previous Close | 44.77 |
| Price Eps Current Year | 13.290273 |
| Price Hint | 2 |
| Price To Book | 2.565797 |
| Price To Sales Trailing12 Months | 3.219451 |
| Profit Margins | 0.17294 |
| Quick Ratio | 0.98 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.48387 |
| Region | US |
| Regular Market Change | -0.119999 |
| Regular Market Change Percent | -0.268034 |
| Regular Market Day High | 45.43 |
| Regular Market Day Low | 44.3601 |
| Regular Market Day Range | 44.3601 - 45.43 |
| Regular Market Open | 45.34 |
| Regular Market Previous Close | 44.77 |
| Regular Market Price | 44.65 |
| Regular Market Time | 1,783,972,802 |
| Regular Market Volume | 11,862,827 |
| Return On Assets | 0.060749996 |
| Return On Equity | 0.14661 |
| Revenue Growth | 0.116 |
| Revenue Per Share | 13.907 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 1,486,355,179 |
| Shares Percent Shares Out | 0.0188 |
| Shares Short | 27,938,624 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 57,491,117 |
| Short Name | Boston Scientific Corporation |
| Short Percent Of Float | 0.0188 |
| Short Ratio | 1.27 |
| Source Interval | 15 |
| State | MA |
| Symbol | BSX |
| Target High Price | 106.0 |
| Target Low Price | 55.0 |
| Target Mean Price | 73.34483 |
| Target Median Price | 70.0 |
| Total Cash | 1,452,999,936 |
| Total Cash Per Share | 0.978 |
| Total Debt | 11,029,000,192 |
| Total Revenue | 20,614,000,640 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 2.39 |
| Trailing P E | 18.682009 |
| Trailing Peg Ratio | 0.5534 |
| Triggerable | 1 |
| Two Hundred Day Average | 76.8372 |
| Two Hundred Day Average Change | -32.187195 |
| Two Hundred Day Average Change Percent | -0.4189012 |
| Type Disp | Equity |
| Volume | 11,862,827 |
| Website | https://www.bostonscientific.com |
| Zip | 01,752-1234 |